BeiGene Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (19)

Latest Posts

About This Stock More About This Stock
Week In Review: Shanghai's I-Mab Plans $100 Million NASDAQ IPO On January 16
Article By: ChinaBio® Today
Sunday, January 5, 2020 10:20 AM EST
I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the NASDAQ exchange at a market value of $750 million. The company plans to offer 7.4 million shares between $12 and $15.
In this article: BGNE, LPTX
Read
Week In Review: Ally Bridge Leads $140 Million Of Investments In Three Medical Device Companies
Article By: ChinaBio® Today
Saturday, December 21, 2019 5:09 PM EST
Ally Bridge Group, a Hong Kong-New York life science investment firm, announced it has led $140 million of investments in three new medical device companies, bringing its 18-month total to more than $500 million in private life science companies.
In this article: BGNE, TCON
Read
Week In Review: AlphaMab Raises $234 Million In Hong Kong IPO; Climbs 35% In First Trading Session
Article By: ChinaBio® Today
Saturday, December 14, 2019 5:09 PM EST
Alphamab Oncology raised $234 million in a Hong Kong IPO and traded 35% higher from its offering price to a market cap of $1.2 billion. The company has a PD-L1 candidate that could be approved in China in 2020 and two bispecifics in Phase II tests.
In this article: AZN, BGNE
Read
Week In Review: BeiGene's BTK Inhibitor Approved In US And China Approval For PD-1 Expected In Two Months
Article By: ChinaBio® Today
Saturday, November 16, 2019 4:09 PM EST
Beijing's BeiGene had an outstanding week: its BTK drug, Brukinsa™, was approved for US use to treat mantle cell lymphoma, and its PD-1 candidate is poised for China approval before the end of the year to treat classical Hodgkin’s lymphoma.
In this article: HCM, BGNE, ASLN
Read
Week In Review: AstraZeneca Announces $1 Billion Fund For China Life Science Startups
Article By: ChinaBio® Today
Saturday, November 9, 2019 6:15 PM EST
Deals, financings, trials and approvals in China biotech this past week.
In this article: AZN, SCR, CICC, BGNE
Read

PARTNER HEADLINES

Latest Tweets for $BGNE

No tweets yet!